MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition
Rhea-AI Summary
MediciNova (NASDAQ:MNOV) has received a Notice of Allowance from the U.S. Patent and Trademark Office for a new patent covering MN-166 (ibudilast) for post-COVID conditions. The Method of Use patent covers administering ibudilast to alleviate various post-COVID symptoms, including anxiety, fatigue, depression, and shortness of breath. The patent allows for multiple administration methods and dosing regimens, either alone or in combination with other active agents.
The patent is expected to expire no earlier than November 2042, providing extended exclusivity for MediciNova. The company is currently conducting a Phase 2/3 clinical trial in Long COVID in collaboration with University Health Network in Canada. MediciNova plans to initiate discussions with Health Canada for a New Drug Application if the RECLAIM study shows positive results.
Positive
- Received Notice of Allowance for new patent covering MN-166 (ibudilast) for post-COVID conditions
- Patent expected to expire no earlier than November 2042, providing extended market exclusivity
- Patent covers multiple administration methods and dosing regimens, enhancing flexibility in treatment options
- Ongoing Phase 2/3 clinical trial for Long COVID in collaboration with University Health Network in Canada
Negative
- None.
News Market Reaction – MNOV
On the day this news was published, MNOV gained 14.50%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
LA JOLLA, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), announces that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application, which covers MN-166 (ibudilast) for post-COVID conditions. The Method of Use patent covers administering a therapeutically effective doses of ibudilast (or a pharmaceutically acceptable salt thereof) to alleviate a range of post-COVID conditions including anxiety, fatigue, depression, shortness of breath, post-traumatic stress disorder, chest tightness, palpitations, smell or taste dysfunction, sleep difficulties, hair loss, and rash.
The claim method allows for MN-166 (ibudilast) to be administered alone or in combination with other active agents, including corticosteroids, NSAIDs, SSRIs, and more. The allowed claims cover oral administration, intravenous administration, subcutaneous injection, intramuscular injection, and inhalation administration. The allowed claims cover a wide range of doses, a range of different dosing frequencies, and a range of different treatment periods. Once issued, this patent is expected to expire no earlier than November 2042.
Kazuko Matsuda, M.D., Ph.D., M.P.H., MediciNova’s Chief Medical Officer commented, “This additional patent for ibudilast provides additional opportunities for us to maintain exclusivity in areas where research is underway. We remain dedicated to addressing the complex and persistent health challenges posed by COVID-19 through key partnerships, such as our current collaboration with University Health Network in Canada, where a Phase 2/3 clinical trial in Long COVID is ongoing. We believe that ibudilast may offer hope to millions of patients suffering from post-COVID conditions, providing a versatile and effective therapeutic option. Since we have committed to move forward to apply New Drug Application when the study shows positive outcome, we plan to initiate the discussion with Health Canada when the RECLAIM study shows the positive data.”
About MN-166 (ibudilast)
MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF). It is in late-stage clinical development for the treatment of neurodegenerative diseases such as ALS (amyotrophic lateral sclerosis), progressive MS (multiple sclerosis), and DCM (degenerative cervical myelopathy); and is also in development for glioblastoma, Long COVID, CIPN (chemotherapy-induced peripheral neuropathy), and substance use disorder. In addition, MN-166 (ibudilast) was evaluated in patients that are at risk for developing acute respiratory distress syndrome (ARDS).
About MediciNova
MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Based on two compounds, MN-166 (ibudilast) and MN-001 (tipelukast), with multiple mechanisms of action and strong safety profiles, MediciNova has 11 programs in clinical development. MediciNova’s lead asset, MN-166 (ibudilast), is currently in Phase 3 for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM) and is Phase 3-ready for progressive multiple sclerosis (MS). MN-166 (ibudilast) is also being evaluated in Phase 2 trials in Long COVID and substance dependence. MN-001 (tipelukast) was evaluated in a Phase 2 trial in idiopathic pulmonary fibrosis (IPF) and a second Phase 2 trial in non-alcoholic fatty liver disease (NAFLD) is ongoing. MediciNova has a strong track record of securing investigator-sponsored clinical trials funded through government grants.
Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of MN-166, MN-001, MN-221, and MN-029. These forward-looking statements may be preceded by, followed by, or otherwise include the words "believes," "expects," "anticipates," "intends," "estimates," "projects," "can," "could," "may," "will," "would," “considering,” “planning” or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of MN-166, MN-001, MN-221, and MN-029 and risks of raising sufficient capital when needed to fund MediciNova's operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova's collaborations with third parties, the availability of funds to complete product development plans and MediciNova's ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2023 and its subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.
INVESTOR CONTACT:
David H. Crean, Ph.D.
Chief Business Officer
MediciNova, Inc
info@medicinova.com
FAQ
What is the new patent MediciNova (MNOV) received for MN-166 (ibudilast)?
When is the expected expiration date for MediciNova's (MNOV) new patent on MN-166 (ibudilast)?
What clinical trial is MediciNova (MNOV) currently conducting for MN-166 (ibudilast) in Long COVID?
What are MediciNova's (MNOV) plans if the RECLAIM study for MN-166 (ibudilast) shows positive results?
